2-hydroxy-1-[4-(5-methyl-2-phenyl-1H-indole-7-yl)amino-piperidine-1-yl]-ethanone | 1120333-33-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-hydroxy-1-[4-(5-methyl-2-phenyl-1H-indole-7-yl)amino-piperidine-1-yl]-ethanone
• 英文别名: 2-hydroxy-1-[4-(5-methyl-2-phenyl-1H-indol-7-yl)aminopiperidin-1-yl]ethanone；2-hydroxy-1-[4-(5-methyl-2-phenyl-1H-indole-7-ylamino)-piperidine-1-yl]-ethanone；2-Hydroxy-1-[4-(5-methyl-2-phenyl-1H-indol-7-yl)amino-piperidin-1-yl]-ethanone；2-hydroxy-1-[4-(5-methyl-2-phenyl-1H-indol-7-ylamino)-piperidin-1-yl]-ethanone；2-hydroxy-1-[4-[(5-methyl-2-phenyl-1H-indol-7-yl)amino]piperidin-1-yl]ethanone
• CAS: 1120333-33-6
• 化学式: C₂₂H₂₅N₃O₂
• 分子量: 363.459
• InChiKey: XKSHTFDLDICLPH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  68.4
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  羟基乙酸 、 (5-methyl-2-phenyl-1H-indole-7-yl)-piperidine-4-yl-amine 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 以43%的产率得到2-hydroxy-1-[4-(5-methyl-2-phenyl-1H-indole-7-yl)amino-piperidine-1-yl]-ethanone
  参考文献：
  名称：

  INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT

  摘要：

  本发明涉及一种用于保存细胞、组织和器官的组合物，其中包括作为活性成分的式（1）的吲哚和吲唑化合物，或其药用可接受的盐或异构体，对于预防由冷藏、移植手术或移植后再灌注引起的器官、分离的细胞系统或组织的损伤具有有效性；一种保存方法；以及该组合物的制备方法。

  公开号：

  US20100291533A1

文献信息

• INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS
  申请人：Kim Soon Ha

  公开号：US20100197673A1

  公开（公告）日：2010-08-05

  The present invention relates to indole or indazole compounds, pharmaceutically acceptable salts or isomers thereof which are useful for the prevention or treatment of cellular necrosis and necrosis-associated diseases. The present invention also relates to a method and a composition for the prevention or treatment of cellular necrosis and necrosis-associated diseases, comprising said indole or indazole compounds as an active ingredient.

  本发明涉及吲哚或吲唑化合物，其药学上可接受的盐或异构体，用于预防或治疗细胞坏死和与坏死相关的疾病。本发明还涉及一种用于预防或治疗细胞坏死和与坏死相关疾病的方法和组合物，包括所述吲哚或吲唑化合物作为活性成分。
• [EN] INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS<br/>[FR] COMPOSÉS D'INDOLE ET D'INDAZOLE EN TANT QU'INHIBITEURS DE NÉCROSE CELLULAIRE
  申请人：LG LIFE SCIENCES LTD

  公开号：WO2009025478A1

  公开（公告）日：2009-02-26

  The present invention relates to indole or indazole compounds, pharmaceutically acceptable salts or isomers thereof which are useful for the prevention or treatment of cellular necrosis and necrosis-associated diseases. The present invention also relates to a method and a composition for the prevention or treatment of cellular necrosis and necrosis-associated diseases, comprising said indole or indazole compounds as an active ingredient.

  本发明涉及吲哚或吲唑化合物，其药用盐或异构体，可用于预防或治疗细胞坏死和与坏死相关的疾病。本发明还涉及一种用于预防或治疗细胞坏死和与坏死相关疾病的方法和组合物，包括所述吲哚或吲唑化合物作为活性成分。
• 세포괴사 저해제로서의 인돌 및 인다졸 화합물
  申请人：LG Life Sciences Ltd. 주식회사 엘지생명과학(120020308350) Corp. No ▼ 110111-2581183

  公开号：KR101511771B1

  公开（公告）日：2015-04-14

  본 발명은 하기 화학식 (1)의 화합물, 약제학적으로 허용되는 그의 염 또는 이성체, 및 이를 활성 성분으로 함유함을 특징으로 하는 세포괴사 및 관련 질환을 예방 또는 치료하기 위한 방법 및 조성물에 관한 것이다. [화학식 1] 상기 식에서 R1, R2, R3, R4, R5, R6, A, X, n 및 m은 명세서에 정의한 바와 같다.

  本发明涉及一种用于预防或治疗细胞凋亡和相关疾病的方法和组合物，其特征在于包含以下化学式（1）的化合物，其允许的药理盐或同分异构体，并将其包含为活性成分。[化学式1] 在上述公式中，R1、R2、R3、R4、R5、R6、A、X、n和m如所述规范中定义。
• Indole and indazole compounds as an inhibitor of cellular necrosis
  申请人：Kim Soon Ha

  公开号：US08436038B2

  公开（公告）日：2013-05-07

  The present invention relates to indole or indazole compounds, pharmaceutically acceptable salts or isomers thereof which are useful for the prevention or treatment of cellular necrosis and necrosis-associated diseases. The present invention also relates to a method and a composition for the prevention or treatment of cellular necrosis and necrosis-associated diseases, comprising said indole or indazole compounds as an active ingredient.

  本发明涉及吲哚或吲唑化合物，其药学上可接受的盐或异构体，用于预防或治疗细胞坏死和与坏死相关的疾病。本发明还涉及一种预防或治疗细胞坏死和与坏死相关的疾病的方法和组合物，其包括所述吲哚或吲唑化合物作为活性成分。
• PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING OPHTHALMIC DISORDERS
  申请人：CATHOLIC UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

  公开号：US20150038500A1

  公开（公告）日：2015-02-05

  The invention relates to a pharmaceutical composition for preventing or treating an ophthalmologic disease comprising a compound of formula (1) as defined in the specification, or a pharmaceutically acceptable salt or isomer thereof as an active ingredient. Also, the invention relates to a composition for cleansing or preserving a contact lens comprising the above active ingredient.